Tioxazafen Patent Landscape Analysis

Tioxazafen is a seed-treatment nematicide developed by Bayer / Monsanto, commercialised through the Acceleron® NemaStrike brand.

The retained landscape covers 51 patent families across 26 consolidated owner groups. Two-active combination is the thickest protection layer (34 families), with manufacturing route and formulation claims providing additional constraint.

40 of the 51 retained families carry a grant or national pending reading. 31 families are held by China-based applicants. 1 live family has a nominal term ending within five years. Position as at October 2026.

This 40-page report provides a seven-part analysis covering ownership, active-ingredient manufacture, single-active formulation, fixed-dose mixtures, national market entry and owner profiles, with route-level remaining-space notes and an appendix owner directory.

Not a freedom-to-operate opinion.